# Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

> **NCT01853800** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 14 (actual)

## Conditions studied

- Biological Availability

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT01853800
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-07
- **Final completion:** 2013-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853800, "Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01853800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*